These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 6203759)
1. Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Chiueh CC; Markey SP; Burns RS; Johannessen JN; Pert A; Kopin IJ Eur J Pharmacol; 1984 Apr; 100(2):189-94. PubMed ID: 6203759 [TBL] [Abstract][Full Text] [Related]
2. Neurochemical changes in the substantiae nigrae and caudate nuclei following acute unilateral intranigral infusions of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Sirinathsinghji DJ; Whittington PE; Audsley AR Brain Res; 1986 Dec; 399(2):339-45. PubMed ID: 2435361 [TBL] [Abstract][Full Text] [Related]
3. Biochemical and functional evidence for a marked dopamine releasing action of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (NMPTP) in mouse brain. Pileblad E; Nissbrandt H; Carlsson A J Neural Transm; 1984; 60(3-4):199-203. PubMed ID: 6084705 [TBL] [Abstract][Full Text] [Related]
4. The influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the levels of dopamine, serotonin and their metabolites in the caudate nucleus of the rat. Russ H; Henning K; Eckhardt H; Przuntek H Arzneimittelforschung; 1985; 35(2):481-2. PubMed ID: 2581589 [TBL] [Abstract][Full Text] [Related]
5. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Burns RS; Chiueh CC; Markey SP; Ebert MH; Jacobowitz DM; Kopin IJ Proc Natl Acad Sci U S A; 1983 Jul; 80(14):4546-50. PubMed ID: 6192438 [TBL] [Abstract][Full Text] [Related]
6. The toxic actions of MPTP and its metabolite MPP+ are not mimicked by analogues of MPTP lacking an N-methyl moiety. Bradbury AJ; Costall B; Domeney AM; Testa B; Jenner PG; Marsden CD; Naylor RJ Neurosci Lett; 1985 Oct; 61(1-2):121-6. PubMed ID: 2417166 [TBL] [Abstract][Full Text] [Related]
8. Partial protection from the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by Pro-Leu-Gly-NH2(PLG; MIF-1). Sheng JG; Xu DL; Yu HZ; Xu XR; Tang QM Life Sci; 1987 May; 40(20):2007-10. PubMed ID: 2437428 [TBL] [Abstract][Full Text] [Related]
9. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat. Harik SI; Schmidley JW; Iacofano LA; Blue P; Arora PK; Sayre LM J Pharmacol Exp Ther; 1987 May; 241(2):669-76. PubMed ID: 2437293 [TBL] [Abstract][Full Text] [Related]
11. The neurotoxic actions of 6-hydroxydopamine infused into the rat substantia nigra. Bradbury AJ; Costall B; Domeney AM; Jenner PJ; Marsden CD; Naylor RJ Neurosci Lett; 1986 Jun; 67(2):208-12. PubMed ID: 2425303 [TBL] [Abstract][Full Text] [Related]
12. Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. Elsworth JD; Deutch AY; Redmond DE; Sladek JR; Roth RH Life Sci; 1987 Jan; 40(2):193-202. PubMed ID: 3491946 [TBL] [Abstract][Full Text] [Related]
13. Acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) reduces dopamine and serotonin but accelerates norepinephrine metabolism in the rat brain. Effect of chronic pretreatment with MPTP. Enz A; Hefti F; Frick W Eur J Pharmacol; 1984 May; 101(1-2):37-44. PubMed ID: 6086364 [TBL] [Abstract][Full Text] [Related]
14. Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine on neostriatal dopamine in mice. Heikkila RE; Cabbat FS; Manzino L; Duvoisin RC Neuropharmacology; 1984 Jun; 23(6):711-3. PubMed ID: 6611514 [TBL] [Abstract][Full Text] [Related]
15. Behavioral and biochemical changes following acute administration of MPTP and MPP+. Tadano T; Satoh N; Sakuma I; Matsumura T; Kisara K; Arai Y; Kinemuchi H Life Sci; 1987 Mar; 40(13):1309-18. PubMed ID: 2436017 [TBL] [Abstract][Full Text] [Related]
16. Asymmetric dopamine and serotonin metabolism in nigrostriatal and limbic structures of the trained circling rat. Yamamoto BK; Freed CR Brain Res; 1984 Apr; 297(1):115-9. PubMed ID: 6202362 [TBL] [Abstract][Full Text] [Related]
17. The protective effect of 1-tert.butyl-4,4-diphenylpiperidine against the nigrostriatal neurodegeneration caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Przuntek H; Russ H; Henning K; Pindur U Life Sci; 1985 Sep; 37(13):1195-200. PubMed ID: 2413325 [TBL] [Abstract][Full Text] [Related]
18. Dissociation of serotoninergic and dopaminergic components in acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Mitra N; Mohanakumar KP; Ganguly DK Brain Res Bull; 1992 Mar; 28(3):355-64. PubMed ID: 1350496 [TBL] [Abstract][Full Text] [Related]
19. Comparison of 1-methyl-4-(p-chlorophenyl)-1,2,3,6-tetrahydropyridine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and p-chloroamphetamine as monoamine depletors. Fuller RW; Hemrick-Luecke SK; Robertson DW Res Commun Chem Pathol Pharmacol; 1985 Oct; 50(1):57-65. PubMed ID: 2417293 [TBL] [Abstract][Full Text] [Related]
20. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Jenner P; Rupniak NM; Rose S; Kelly E; Kilpatrick G; Lees A; Marsden CD Neurosci Lett; 1984 Sep; 50(1-3):85-90. PubMed ID: 6436758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]